Epidermal growth factor receptor – targeted molecular therapeutics for head and neck squamous cell carcinoma

By Egloff Ann Marie   Grandis Jennifer  

Expert Opinion on Therapeutic Targets, Vol. 10, Iss. 5, 2006-10 ,pp. : 639-647

Informa Healthcare

Access to resources Recommend Favorite

Treatment of Squamous Cell Carcinoma of the Head and Neck in the Metastatic and Refractory Settings: Advances in Chemotherapy and the Emergence of Small Molecule Epidermal Growth Factor Receptor Kinase Inhibitors

By  

Current Cancer Drug Targets, Vol. 7, Iss. 7, 2007-11 ,pp. : 666-673

Bentham Science Publishers

Access to resources Recommend Favorite

A review of erlotinib – an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor

By Iyer Renuka   Bharthuar Anubha  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 2, 2010-02 ,pp. : 311-320

Informa Healthcare

Access to resources Recommend Favorite

A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

By Reckamp Karen L.   Giaccone Giuseppe   Camidge D. Ross   Gadgeel Shirish M.   Khuri Fadlo R.   Engelman Jeff A.   Koczywas Marianna   Rajan Arun   Campbell Alicyn K.   Gernhardt Diana   Ruiz-Garcia Ana   Letrent Stephen   Liang Jane   Taylor Ian   O'Connell Joseph P.   Jänne Pasi A.  

Cancer, Vol. 120, Iss. 8, 2014-04 ,pp. : 1145-1154

Blackwell Publishing

Access to resources Recommend Favorite

Prognostic Role of P27kip1 and Epidermal Growth Factor Receptor in Transitional Cell Carcinoma of the Bladder

By Valentine Andrea   Ritchie Joan L.   Nevin Gerald B.   McKeown Stephanie R.  

UroOncology, Vol. 2, Iss. 1, 2002-01 ,pp. : 41-46

Ashgate Publishing Ltd

Access to resources Recommend Favorite